Cerulean Pharma (CERU) Higher on $20M Purchase Agreement with Aspire Capital, Announces Novartis (NVS) Collaboration
Cerulean Pharma (NASDAQ: CERU) is trading higher following the effect of a $20 million common stock purchase agreement and a registration rights agreement with Aspire Capital Fund, LLC. Immediately following the execution of the purchase agreement, announced this morning, Aspire purchased 800,000 shares of common stock for $1.25 per share. The clinical-stage company developing nanoparticle-drug conjugates (NDCs) also this morning announced its strategic collaboration with Novartis (NYSE: NVS) to develop NDC product candidates combining Cerulean’s proprietary Dynamic Tumor Targeting™ technology with Novartis’ proprietary compounds directed at up to five targets. To view the full press releases, visit: http://nnw.fm/0Wzlg and http://nnw.fm/k20QU…